Yale Cancer Center Smilow Cancer Hospital - Episode 18
Findings from a new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity, which could help develop a new treatment strategy to benefit patients with melanoma and other cancers.
A new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity. These findings could help develop a new treatment strategy to benefit patients with melanoma and other cancers, especially those who do not respond to current therapies. The research is published online today in the journal Nature.
“These results are exciting as we discovered fundamental roles of some poorly studied genetic elements in immune responses and identified a new way to stimulate the ability of our immune system to fight cancer,” said Qin Yan, PhD, Associate Professor of Pathology and Director of the Epigenetics Program in the Department of Pathology and a member of Yale Cancer Center. “In addition, we showed that this method can be used to overcome the resistance to current cancer immunotherapies.”
In the study, researchers show depletion of the protein KDM5B, which is critical for melanoma maintenance and drug resistance, induces robust adaptive immune responses, and enhances responses to immune checkpoint blockade. KDM5B partners with SETDB1, a protein coding gene, to repress the expression of certain genetic elements such as MMVL30. Expression of these genetic elements stimulates RNA and DNA sensing pathways and subsequent interferon responses, leading to tumor rejection and immune memory.
Yan and his team have been working on the roles of KDM5 proteins in development and cancer for many years. These studies began when researchers sought to understand the roles of KDM5B in melanoma in close collaboration with the lab of fellow Yale researcher Marcus Bosenberg, MD, PhD, a co-corresponding author of the study. Resources and expertise provided by the Yale Center for Immuno-Oncology and the Yale SPORE in Skin Cancer were critical for this research.
“It is urgent to find new strategies to render immunotherapies effective to help treat patients with cancer,” said Bosenberg. “We’re encouraged as now we’re working on dissecting how these genetic elements contribute to cancer and developing specific cancer drugs based on our discovery,” added Yan.
Shang-Min Zhang, PhD, is lead author of the study. Other Yale study authors include Wesley L. Cai, PhD, Xiaoni Liu, PhD, Durga Thakral, PhD, Jiesi Luo, PhD, Lok Hei Chan, PhD, Meaghan K. McGeary, Eric Song, Kim Blenman, PhD, Goran Micevic, MD, PhD, Shlomit Jessel, Yangyi Zhang, Mingzhu Yin, MD, PhD, Carmen J. Booth, DVM, PhD, Lucia B. Jilaveanu, MD, PhD, William Damsky, MD, PhD, Mario Sznol, MD, Harriet Kluger, MD, and Akiko Iwasaki, PhD.
About Yale Cancer Center and Smilow Cancer Hospital
Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.